Samantha C Gouw

List of Publications by Year
in descending order

54	2,626	361413	182427
papers	citations	20 h-index	51 g-index

55	55	55	1377
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Patientâ€reported outcomes in autosomal inherited bleeding disorders: A systematic literature review. Haemophilia, 2022, 28, 197-214.	2.1	7
2	Myocardial infarction due to thrombotic occlusion despite anticoagulation in Kawasaki disease â€“ a case report. BMC Pediatrics, 2022, 22, 85.	1.7	2
3	Measuring anxiety and depression in young adult men with haemophilia using PROMIS. Haemophilia, 2022, 28, .	2.1	3
4	Joint status of patients with nonsevere hemophilia A. Journal of Thrombosis and Haemostasis, 2022, 20, 1126-1137.	3.8	17
5	The bleeding phenotype in people with nonsevere hemophilia. Blood Advances, 2022, 6, 4256-4265.	5.2	10
6	SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders. Journal of Thrombosis and Haemostasis, 2022, 20, 2001-2011.	3.8	6
7	Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001â€“2018. Journal of Thrombosis and Haemostasis, 2021, 19, 645-653.	3.8	48
8	Sports participation is not associated with adherence to prophylaxis in Dutch patients with haemophilia. Haemophilia, 2021, 27, e402-e405.	2.1	3
9	Cardiovascular risk factors among adult patients with haemophilia. International Journal of Hematology, 2021, 113, 884-892.	1.6	6
10	Patientâ€relevant health outcomes for hemophilia care: Development of an international standard outcomes set. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12488.	2.3	20
11	Adherence to prophylaxis and its association with activation of selfâ€management and treatment satisfaction. Haemophilia, 2021, 27, 581-590.	2.1	8
12	Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study. Haemophilia, 2021, 27, 876-885.	2.1	14
13	Treatmentâ€related risk factors for inhibitor development in nonâ€severe hemophilia A after 50 cumulative exposure days: A caseâ€control study. Journal of Thrombosis and Haemostasis, 2021, 19, 2171-2181.	3.8	8
14	Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972â€“2019. Journal of Thrombosis and Haemostasis, 2021, 19, 2394-2406.	3.8	21
15	Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis. Blood, 2021, 138, 2853-2873.	1.4	23
16	Validation of PROMIS Profileâ€29 in adults with hemophilia in the Netherlands. Journal of Thrombosis and Haemostasis, 2021, 19, 2687-2701.	3.8	16
17	The factor VIII treatment history of nonâ€severe hemophilia Aâ€”Response from original authors Abdi et al. Journal of Thrombosis and Haemostasis, 2021, 19, 2642-2644.	3.8	1
18	Prophylactic anticoagulation in children receiving home parenteral nutrition. Journal of Parenteral and Enteral Nutrition, 2021, , .	2.6	5

#	Article	IF	Citations
19	Generic PROMIS item banks in adults with hemophilia for patientâ€reported outcome assessment: Feasibility, measurement properties, and relevance. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12621.	2.3	8
20	Hepatitis C virus in hemophilia: Healthâ€related quality of life after successful treatment in the sixth Hemophilia in the Netherlands study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12616.	2.3	3
21	Patient Perspectives on Novel Treatments in Haemophilia: A Qualitative Study. Patient, 2020, 13, 201-210.	2.7	28
22	The factor VIII treatment history of nonâ€severe hemophilia A. Journal of Thrombosis and Haemostasis, 2020, 18, 3203-3210.	3.8	15
23	Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia Aâ€" A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2020, 11, 563.	4.8	12
24	Hemophilia management: Huge impact of a tiny difference. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 377-385.	2.3	6
25	Patientâ€centred care in haemophilia: Patient perspectives on visualization and participation in decisionâ€making. Haemophilia, 2019, 25, 938-945.	2.1	11
26	Inhibitor incidence in haemophilia A under exclusive use of a thirdâ€generation recombinant factor <scp>VIII</scp> concentrate: results of the <scp>HEMFIL</scp> Cohort Study. British Journal of Haematology, 2019, 186, 152-155.	2.5	5
27	Measurement of joint health in persons with haemophilia: A systematic review of the measurement properties of haemophiliaâ€specific instruments. Haemophilia, 2019, 25, e1-e10.	2.1	31
28	FactorÂVIII products and inhibitor development in previously treated patients with severe or moderately severe hemophiliaÂA: a systematic review. Journal of Thrombosis and Haemostasis, 2018, 16, 1055-1068.	3.8	25
29	Measuring activities and participation in persons with haemophilia: A systematic review of commonly used instruments. Haemophilia, 2018, 24, e33-e49.	2.1	21
30	Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia, 2018, 24, 283-290.	2.1	24
31	Defining patient value in haemophilia care. Haemophilia, 2018, 24, 516-518.	2.1	1
32	Postpartum haemorrhage in an unselected cohort of carriers of haemophilia. Haemophilia, 2018, 24, e256-e259.	2.1	8
33	Preventing or Eradicating Factor VIII Antibody Formation in Patients with Hemophilia A: What Can We Learn from Other Disorders?. Seminars in Thrombosis and Hemostasis, 2018, 44, 531-543.	2.7	9
34	Healthâ€related quality of life questionnaires in individuals with haemophilia: a systematic review of their measurement properties. Haemophilia, 2017, 23, 497-510.	2.1	43
35	Antibody therapies for lymphoma in children. The Cochrane Library, 2016, 2016, CD011181.	2.8	4
36	Secondâ€generation recombinant factor <scp>VIII</scp> and inhibitor risk: interpretation of <scp>RODIN</scp> study findings and implications for patients with haemophilia A. Haemophilia, 2014, 20, e171-4.	2.1	15

#	Article	IF	Citations
37	Similar bleeding phenotype in young children with haemophilia A or B: a cohort study. Haemophilia, 2014, 20, 747-755.	2.1	35
38	Factor VIII Products and Inhibitor Development in Severe Hemophilia A. New England Journal of Medicine, 2013, 368, 231-239.	27.0	383
39	Factor VIII Products and Inhibitors in Severe Hemophilia A. New England Journal of Medicine, 2013, 368, 1456-1457.	27.0	11
40	Identifying Nongenetic Risk Factors for Inhibitor Development in Severe Hemophilia A. Seminars in Thrombosis and Hemostasis, 2013, 39, 740-751.	2.7	24
41	Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood, 2013, 121, 4046-4055.	1.4	287
42	Unraveling the genetics of inhibitors in hemophilia. Blood, 2013, 121, 1250-1251.	1.4	3
43	F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood, 2012, 119, 2922-2934.	1.4	305
44	Prenatal diagnosis for haemophilia: a nationwide survey among female carriers in the Netherlands. Haemophilia, 2012, 18, 584-592.	2.1	25
45	Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients. Haemophilia, 2011, 17, 275-281.	2.1	39
46	Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units. Haemophilia, 2010, 16, 71-79.	2.1	24
47	The Multifactorial Etiology of Inhibitor Development in Hemophilia: Genetics and Environment. Seminars in Thrombosis and Hemostasis, 2009, 35, 723-734.	2.7	101
48	Discordant antibody response in monozygotic twins with severe haemophilia A caused by intensive treatment. Haemophilia, 2009, 15, 712-717.	2.1	10
49	IgG subclasses of antiâ€FVIII antibodies during immune tolerance induction in patients with hemophilia A. British Journal of Haematology, 2008, 142, 644-652.	2.5	82
50	Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood, 2007, 109, 4648-4654.	1.4	449
51	Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood, 2007, 109, 4693-4697.	1.4	220
52	Response: Plasma-derived or recombinant factor VIII products and inhibitors in previously untreated patients with severe hemophilia. Blood, 2007, 110, 1074-1075.	1.4	5
53	Response: Immunogenicity of factor VIII concentrates in patients with hemophilia: the next sensible step. Blood, 2007, 110, 3085-3085.	1.4	1
54	Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. Journal of Thrombosis and Haemostasis, 2007, 5, 1383-1390.	3.8	134